NasdaqCM:SLSBiotechs
SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story
Earlier this week, SELLAS Life Sciences Group reported a first-quarter 2026 net loss of US$8.41 million while confirming its pivotal Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis.
Alongside this, SELLAS strengthened its cash position to US$107.1 million, advanced its SLS009 candidate into a Phase 2 AML trial, and set up a US$150 million at-the-market equity program, underscoring a balance of late-stage and...